Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Core Insights - Annovis Bio, Inc. has published a new article in the peer-reviewed journal Biomolecules detailing the pharmacokinetic profile of a new crystal form of buntanetap, which is being developed for neurodegenerative diseases like Alzheimer's and Parkinson's [1][2]. Group 1: New Crystal Form of Buntanetap - The newly identified dihydrate crystal form of buntanetap offers greater stability compared to the original anhydrous form, which has been used in all previous studies [2]. - The publication confirms that the new crystal form maintains the pharmacokinetic profile and metabolism essential for the drug's therapeutic efficacy [2][4]. Group 2: Clinical Trials and Intellectual Property - The new crystal form of buntanetap is currently being utilized in a pivotal Phase 3 clinical trial (NCT06709014) for early Alzheimer's disease, with key readouts expected in Fall 2026 and Fall 2027 [4]. - This new form extends the intellectual property protection of the lead compound into the 2040s, covering its mechanism of action, therapeutic use, and potential combinations with other drugs [4]. Group 3: Company Commitment and Communication - The company emphasizes its commitment to rigorous analysis of buntanetap to ensure beneficial outcomes for patients [4]. - Annovis Bio is dedicated to developing innovative therapies aimed at improving patient outcomes and quality of life in neurodegenerative diseases [6].